Moolec Science (MLECW) Operating Income (2022 - 2024)
Moolec Science (MLECW) posted Operating Income of -$2.1 million for Q4 2024, up 2.0% sequentially from -$2.1 million in Q3 2024, and down 14.86% YoY from -$2.4 million in Q1 2024.
Moolec Science (MLECW) Operating Income (2022 - 2024) Analysis & Trends
Moolec Science has reported Operating Income for 3 years, with the latest figure at -$2.1 million in Q4 2024.
- Quarterly Operating Income fell 14.86% year-over-year to -$2.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$9.1 million (up 4.0% YoY) and the FY2024 annual result came in at -$9.0 million, down 35.9% from the prior year.
- Operating Income advanced to -$2.1 million in Q4 2024 per MLECW's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$472416.0 in Q4 2022 and troughed at -$4.1 million in Q2 2023.
- A 3-year average of -$1.8 million and a median of -$1.9 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income sank 279.55% in 2023, then rose 28.0% in 2024.
- Over 3 years, Operating Income stood at -$472416.0 in 2022, then tumbled by 279.55% to -$1.8 million in 2023, then slipped by 14.86% to -$2.1 million in 2024.
- According to Business Quant data, Operating Income over the past three periods registered -$2.1 million, -$2.1 million, and -$2.9 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -2.10 Mn |
| Jun 30, 2024 | -2.94 Mn |
| Mar 31, 2024 | -2.04 Mn |
| Dec 31, 2023 | -1.79 Mn |
| Sep 30, 2023 | -2.27 Mn |
| Jun 30, 2023 | -4.08 Mn |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -472,416.00 |
| Sep 30, 2022 | -718,315.00 |
| Jun 30, 2022 | -1.30 Mn |
| Mar 31, 2022 | -519,962.00 |